Welcome to our dedicated page for Niagen Bioscience SEC filings (Ticker: NAGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Niagen Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Niagen Bioscience's regulatory disclosures and financial reporting.
Niagen Bioscience is registering an additional 4,750,000 shares of its common stock (par value $0.001) for issuance under the 2017 Equity Incentive Plan following a stockholder-approved increase to the plan's share reserve on June 24, 2025. The filing incorporates prior S-8 registrations and references the company's recent annual and quarterly SEC reports for the disclosures that govern these awards. These shares will be available for issuance as employee and director equity awards under the amended plan.
Niagen Bioscience, Inc. has filed a Form S-8 to register 650,000 shares of its common stock for issuance under its Employee Stock Purchase Plan, enabling eligible employees and subsidiaries to acquire company shares through that plan. The Registration Statement incorporates the company’s recent annual, quarterly and current reports and refers to its previously filed description of common stock so investors can find detailed financial and disclosure history by reference.
The filing describes standard Delaware-law indemnification protections for directors and officers, the company’s authority to purchase insurance for such persons, and confirms key corporate governance documents and the ESPP are attached as exhibits. The statement is procedural and does not present standalone financial results or new material transactions that change the company’s financial condition.
Niagen Bioscience (Nasdaq:NAGE) filed a Form 8-K detailing the outcomes of its 24 June 2025 Annual Meeting.
- 2017 Equity Incentive Plan: share reserve increased by 4,750,000 shares.
- New ESPP: 650,000 shares available; purchase price set at 85% of the lower of the offering- or purchase-date close.
- All eight directors re-elected; Crowe LLP ratified as auditor.
- Advisory say-on-pay passed (54,899,483 for / 1,160,619 against).
The amended plan (Ex. 10.1) and ESPP (Ex. 10.2) were filed; no other material changes were disclosed.
Form 4 filing reveals that Wendy Wing Tak Yu, Director at Niagen Bioscience (NAGE), received a stock option grant on June 24, 2025. The derivative securities transaction details include:
- Granted 20,000 stock options to purchase common stock
- Exercise price set at $14.13 per share
- 100% vesting scheduled for June 24, 2026
- Options expire on June 23, 2035
The filing, submitted by attorney-in-fact Jeong James Lee on June 26, 2025, indicates a standard director compensation grant with a one-year cliff vesting schedule. This represents a new position in derivative securities for the director, with direct ownership of all 20,000 options.
Niagen Bioscience (NAGE) Director Kristin Patrick received a stock option grant for 20,000 shares of common stock on June 24, 2025. The options were granted with the following terms:
- Exercise price set at $14.13 per share
- 100% vesting scheduled for June 24, 2026
- Options expire on June 23, 2035
- Total grant value will be determined by stock price appreciation above $14.13
The Form 4 filing was signed by Attorney-in-Fact Jeong James Lee on June 26, 2025. This equity compensation grant appears to be part of the company's director compensation program, providing long-term alignment with shareholder interests through a 10-year exercise window following the one-year cliff vesting period.
Steven D. Rubin, Director of Niagen Bioscience, was granted 20,000 stock options on June 24, 2025. The options have the following key terms:
- Exercise price set at $14.13 per share
- Vesting schedule: 100% vesting on June 24, 2026
- Expiration date: June 23, 2035
- Securities underlying the options: Common Stock
- Direct ownership form
The Form 4 filing was signed by James Lee as attorney-in-fact on June 25, 2025. This equity compensation grant appears to be part of the company's director compensation program, providing long-term alignment with shareholder interests through a one-year cliff vesting requirement.
Director Gary Ng Wang Yu of Niagen Bioscience (NAGE) was granted stock options on June 24, 2025. The key details of this Form 4 filing include:
- Received 20,000 stock options to purchase common stock
- Exercise price set at $14.13 per share
- Options will vest 100% on June 24, 2026
- Options expire on June 23, 2035
- Transaction reported as a direct ownership
This grant appears to be part of the company's director compensation program. The one-year cliff vesting schedule suggests a standard annual director equity award structure. The 10-year exercise period from the grant date provides long-term alignment with shareholder interests.
FAQ
What is the current stock price of Niagen Bioscience (NAGE)?
What is the market cap of Niagen Bioscience (NAGE)?
